SAN DIEGO, May  07, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of enGene Therapeutics Inc. (NASDAQ:ENGN). The investigation focuses on enGene&#39;s executive

ENGN

enGene Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

enGene Faces Legal Scrutiny After Disappointing Trial Results

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>SAN DIEGO, May  07, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of enGene Therapeutics Inc. (NASDAQ:ENGN). The investigation focuses on enGene&amp;#39;s executive</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>enGene Therapeutics is under investigation by Johnson Fistel following disappointing interim results from its Phase 2 LEGEND trial. The lower-than-expected response rates could open avenues for investor claims against the company, suggesting potential volatility and legal challenges ahead.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Johnson Fistel investigating potential claims against enGene&#039;s executives.</li><li>enGene&#039;s Phase 2 trial results disappointed, affecting investor confidence.</li><li>Investor losses may be recoverable under federal securities laws.</li><li>Stock price declined sharply following negative trial disclosures.</li><li>Durability outcomes are below expectations, prompting legal scrutiny.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Johnson Fistel, PLLP (NA)</strong>: Law firm investigating enGene for potential securities claims.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This falls under Corporate Developments due to legal scrutiny impacting company management and shareholder rights, aligning with ongoing investor concerns.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Negative trial results led to sharp stock decline and investor losses.</li><li>Legal investigation could lead to further stock volatility.</li><li>Potential recovery claims may draw investor attention and sentiment degradation.</li><li>Ongoing trial data releases may continue to impact stock performance.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>54% complete response rate at any time reported.</li><li>Only 43% complete response rate at 6 months observed.</li><li>12-month duration of response estimated at 25%.</li><li>Complete response rates fell to 39% and 32% for latest 32 patient analysis.</li><li>Investigation commenced after recent disclosures on May 7, 2026.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Sell ENGN short due to impending legal scrutiny and deteriorating trial confidence over the next 3-6 months.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>SAN DIEGO, May  07, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of enGene Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ENGN">ENGN</a>). The investigation focuses on enGene's executive officers and whether investor losses may be recovered under federal securities laws.</p>  <p><strong>What if I purchased enGene securities?</strong><br></br>If you purchased enGene securities and suffered losses on your investment, join our investigation now: <a href="https://www.globenewswire.com/Tracker?data=UEsG-k4O4xBPV27YJZiLUT3VFoA8iFx1hooYVg8kyll7T0vf__BP6tcEJ91Jw-hR6qfjRT9wMHF_5n651l_B1LNK3bf94VG1FEvydRc6ATCrxkzQ2uMG97twGYmNYRU3hHdMLu22YKtKlD8g9U03JIQgA3P507qg8mXuls-mqRxB3SdGBWHnjS1oPLLacO0P" rel="nofollow" target="_blank">Click here to join the investigation</a>.</p>  <p>Or for more information, contact Jim Baker at <a href="mailto:jimb@johnsonfistel.com">jimb@johnsonfistel.com</a> or (619) 814-4471.</p>  <p>There is no cost or obligation to you.</p>  <p><strong>Background of the investigation</strong><br></br>On May 7, 2026, enGene announced updated interim results from the pivotal cohort of its ongoing Phase 2 LEGEND trial of detalimogene voraplasmid in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer.</p>  <p>Among other things, enGene disclosed that patients treated with detalimogene achieved a 54% complete response rate at any time and a 43% complete response rate at six months.</p>  <p>However, enGene also disclosed that the Kaplan-Meier estimate of 12-month duration of response was 25%. In addition, the Company stated that "durability outcomes to date are not what we hoped."</p>  <p>enGene further disclosed that, among the 32 patients who had their first disease assessment after the Company's last data analysis, complete response rates were lower than previously reported results. For those patients, the complete response rate at any time was 39%, and the complete response rate at six months was 32%.</p>  <p>Following this disclosure, enGene's stock price declined sharply, damaging investors.</p>  <p>In light of this disclosure, Johnson Fistel is investigating whether enGene complied with the federal securities laws. If you suffered losses from your investment in enGene stock, contact Johnson Fistel.</p>  <p><strong>About Johnson Fistel, PLLP &#x7C; Securities Fraud &amp; Investor Rights</strong><br></br>Johnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits and also assists foreign investors who purchased shares on U.S. exchanges. To learn more, visit <a href="https://www.globenewswire.com/Tracker?data=ImIR_NcnOAX6bPYScW4mFG_IOT94G55tV9RgCGpw9iXJzq8ShuSGzakb6qYWZ7xtAFL7KC8W_VLOcn_yfQlCoV81napUkj-XOGS34-b05wY=" rel="nofollow" target="_blank">www.johnsonfistel.com</a>.</p>  <p><strong>Achievements</strong><br></br>In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services, reflecting the firm's effectiveness in advocating for investors and recovering approximately $90,725,000 for clients in cases where it served as lead or co-lead counsel.</p>  <p>Attorney advertising.</p>  <p>Past results do not guarantee future outcomes.</p>  <p>Services may be performed by attorneys in any of our offices.</p>  <p>Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.</p>  <p><strong>Contact</strong><br></br>Johnson Fistel, PLLP<br></br>501 W. Broadway, Suite 800<br></br>San Diego, CA 92101<br></br>James Baker, Investor Relations – or – Frank J. Johnson, Esq.<br></br>(619) 814-4471 &#x7C; <a href="mailto:jimb@johnsonfistel.com">jimb@johnsonfistel.com</a> &#x7C;</p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTcxNTkwMiM3NTkxMTE0IzIxODE3ODk="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/ZjhlYmJkMDAtY2JiNC00N2Y4LWIyMDktZWRmYjI4ODA1NzVlLTExOTMzNTgtMjAyNi0wNS0wNy1lbg==/tiny/Johnson-Fistel-PLLP.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/bb2e6cf6-9d53-4d2e-a5d2-759cdd3b516c"><img src="https://ml.globenewswire.com/media/bb2e6cf6-9d53-4d2e-a5d2-759cdd3b516c/small/johnson-fistel-jpg.jpg" border="0" width="150" height="150" alt="Primary Logo"></img></a></p>

enGene Therapeutics is under investigation by Johnson Fistel following disappointing interim results from its Phase 2 LEGEND trial. The lower-than-expected response rates could open avenues for investor claims against the company, suggesting potential volatility and legal challenges ahead.

enGene Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News